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Background/objective
There are no randomized trials on the comparative effectiveness of radical prostatectomy (RP) and radiotherapy (RT) for 
high-risk prostate cancer. Our aim was to compare treatment outcomes of high-risk prostate cancer after RP and RT, including 
overall survival (OS), biochemical-progression-free survival (bPFS) and disease-progression-free survival (dPFS), using two 
cancer treatments centers’ patient data.
Methods
Data on high-risk prostate cancer patients between 2005 and 2009 were retrospectively reviewed in two cancer centers: Na-
tional Cancer Institute, Vilnius, Lithuania and N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; 210 patients 
were included in the study group treated with RP (n = 174) or RT (n = 36). The mean follow-up time was 5.6 and 6.6 years, 
respectively.
Results
Lower T stage was an independent predictor of better OS (p = 0.01) and bPFS (p = 0.03). Only the highest Gleason score ≥8 
was significantly predictive of a worse OS (p = 0.05), bPFS (p = 0.02) and dPFS (p = 0.001). A high PSA level was predictive of a 
worse bPFS (p = 0.007 for PSA ≥20) and dPFS (p = 0.008 for ≥20). The treatment modality in this study was insignificant after T 
stage, Gleason score and PSA level adjustment for OS, bPFS survival and dPFS survival (p = 0.17, p = 0.39, p = 0.20).
Originalūs mokslo tiriamieji darbai
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Conclusions
The T stage, Gleason score and pretreatment PSA level are significant factors for OS, bPFS survival, and dPFS survival of high-
risk prostate cancer patients. Treatment option (RP or RT) was not an independent predictor of survival in this study. 
Key words: high-risk prostate cancer, radical prostatectomy, radiotherapy
Įvadas / tikslas
Iki šiol nėra atlikta atsitiktinės atrankos klinikinių tyrimų siekiant palyginti radikalios prostatektomijos (RP) ir spindulinės te-
rapijos (ST) efektyvumą gydant didelės rizikos prostatos vėžį. Šio tyrimo tikslas – naudojant dviejų gydymo centrų duomenis 
įvertinti didelės rizikos prostatos vėžiu sergančių ir RP arba ST gydytų pacientų bendrąjį išgyvenamumą, išgyvenamumą iki 
biocheminio progresavimo ir iki ligos progresavimo.
Pacientai ir metodai
2005–2009 metų duomenys apie didelės rizikos prostatos vėžio ligonius buvo retrospektyviai surinkti dviejuose gydymo 
centruose: Nacionaliniame vėžio institute (Vilnius, Lietuva) ir N. N. Aleksandrovo nacionaliniame vėžio centre (Minskas, Bal-
tarusija). Tyrimo grupę sudarė 210 pacientų, iš kurių 174 taikyta RP, 36 – ST. Vidutinis stebėjimo laikas buvo atitinkamai 5,6 ir 
6,6 metų.
Rezultatai
Pirminis naviko išplitimas (T) buvo susijęs su geresniu bendruoju išgyvenamumu (p = 0,01) ir geresniu išgyvenamumu iki 
biocheminio progresavimo (p  = 0,03). Esant didžiausiam naviko diferenciacijos laipsniui (pagal Gleason ≥8) nustatytas reikš-
mingai blogesnis bendrasis išgyvenamumas (p  = 0,05), išgyvenamumas iki biocheminio progresavimo (p  = 0,02) ir išgyve-
namumas iki ligos progresavimo (p  = 0,001). Blogesnis išgyvenamumas iki biocheminio progresavimo (p = 0,007) ir iki ligos 
progresavimo (p = 0,008) taip pat buvo susijęs su aukštu PSA lygiu (≥ 20 ng/mL). Šioje tyrimo grupėje taikytas gydymas netu-
rėjo reikšmingos įtakos bendrajam išgyvenamumui, išgyvenamumui iki biocheminio progresavimo ir iki ligos progresavimo 
(atitinkamai p = 0,17, p = 0,39, p = 0,20) atsižvelgus į pirminį naviko išplitimą, naviko diferenciaciją ir PSA lygį. 
Išvados
Pirminis naviko išplitimas (T), naviko diferenciacijos laipsnis (pagal Gleason) ir PSA lygis iki gydymo turėjo reikšmingos įtakos 
bendrajam išgyvenamumui, išgyvenamumui iki biocheminio progresavimo ir iki ligos progresavimo didelės rizikos prostatos 
vėžiu sergančių pacientų grupėje. Šiame tyrime taikytas gydymas (RP arba ST) nebuvo nepriklausomas išgyvenamumui įtaką 
darantis veiksnys. 
Reikšminiai žodžiai: didelės rizikos prostatos vėžys, radikali prostatektomija, spindulinė terapija
Introduction
Prostate cancer is the most common cancer in men 
worldwide [1] and the second cause of cancer-related 
death in men in the Western world [2]. The main treat-
ment options for high-risk prostate cancer are radical 
prostatectomy (RP) and radiotherapy (RT). However, 
there is no consensus on which is superior [3], as no 
decisive large prospective randomised clinical trial com-
paring the outcomes of the treatments has been done 
yet. The only two completed trials are inconclusive or 
underpowered [4, 5], and the results of the ongoing 
trials might not be available soon [6]. Therefore, the 
only data sources currently available are retrospective 
studies. Although they are quite numerous, their results 
are controversial as well – most of them favor RP [7], 
but some favor also RT [8–10]. 
The purpose of this study was to compare treat-
ment outcomes of patients with a high-risk prostate 
cancer after RP and RT, including overall survival 
(OS), biochemical-progression-free survival (bPFS), 
and disease-progression-free survival (dPFS), using two 
cancer treatment centers’ patient data. 
Materials and methods
Study population
Data on high-risk prostate cancer patients were collected 
retrospectively in two oncology centers. The National 
Cancer Institute, Vilnius, Lithuania (NCI) is one of 
the biggest prostate cancer treating tertiary health care 
centers in Lithuania. During the study period, high-risk 
prostate cancer patients were treated according to the 
standard hospital treatment protocol which corresponds 
to the Lithuanian Urologist Association recommenda-
tions based on the protocol confirmed by the Lithuanian 
Ministry of Health (2002-08-14, 422). N.N. Alexan-
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drov National Cancer Center of Belarus, Minsk (NCC) 
is the biggest cancer centre in Belarus, where prostate 
cancer patients are concentrated. In the NCC, prostate 
cancer patients were mainly treated surgically, while in 
the NCI both treatment methods were used.
The medical records of patients who presented to 
urology departments at the NCI and the NCC between 
2005 and 2009 were reviewed. High-risk patients were 
defined as T3 or the Gleason 8–10 or PSA > 20 ng/
mL (one criteria) or those who met two of the follow-
ing criteria: T2b or greater; the Gleason score 7; PSA 
10–20 ng/ml. 
Treatment
Prostate cancer patients were treated according to the 
standard treatment protocols. RP is a typical surgical 
procedure with a standard protocol. Prostate, seminal 
vesicles and regional lymph nodes are removed. The 
bladder and the urethra are then reconnected. RT 
patients in this study group were treated with external 
beam radiotherapy to a total dose of 40–72 Gy (for 26 
patients 70 Gy) with a daily dose of 2 Gy delivering five 
fractions per week.
In the RT group, 33 of 36 patients received neoad-
juvant antiandrogen therapy 2–3 months before radio-
therapy, during the therapy and 6 months to 2  years 
after. In the surgery group, for 27 of 174 patients ad-
juvant therapy was used differently in the two centers: 
in the NCI, neoadjuvant the antiandrogen therapy was 
used during the study period and in the NCC adjuvant 
treatment was used if the operation was found to be 
not radical.
Follow-up
The study population includes only patients with 
adequate follow-up data (the last standard medical 
examination no less than 3 years after treatment). In 
both centers, the PSA level is tested every 3 months for 
one year, then every 6 months for the next 3 years, then 
once a year. 
The primary endpoint of interest was overall survival 
(OS). OS was defined as the time from surgery in the 
RP group and the date of radiotherapy in the RT group 
to death from any cause or to 31 December 2012. 
Biochemical-progression-free survival was defined as 
the time from surgery to the PSA level ≥0.2 ng/mL and 
after radiotherapy as a rise of PSA more than 2 ng/mL 
after the nadir had been reached. Disease progression 
was defined as the development of either local disease 
recurrence or distant metastases. 
Statistical analysis
Survival was estimated by the Kaplan–Meier method, 
and the Cox regression analysis was used to assess the 
effects of different variables on patient survival. The 
survival curves were compared using the log-rank test. 
P < 0.05 indicated a statistically significant difference. 
All statistical analyses were performed using the Stata 
Statistical Software version 11.0. (StataCorp. 2009. 
Stata Statistical Software: Release 11.0. College Station, 
TX, USA). 
Results
Study group characteristics
The mean patient age of the whole group was 62.9 years 
(range, 44–77 years), and the mean pretreatment PSA 
level was 20.1 ng/mL (range, 2.0–214.6 ng/mL). The 
characteristics of the patients by treatment group are 
shown in Table 1. 
In total, 174 patients received RP and 36 patients RT 
as the definitive prostate cancer treatment. There were 
no notable imbalances with regard to the mean age, the 
biopsy Gleason score and the mean pretreatment PSA 
level. Patients treated with RP were more likely to have 
the clinical stage T2b–T2c (57.5% vs. 13.9%) and less 
likely to have stage T3 (42.5% vs. 86.1%) as compared 
with patients treated with RT. The mean follow-up time 
was 5.6 years for the RP and 6.6 years for the RT groups.
Treatment outcomes
The outcomes analyzed were the 5-year overall survival 
(OS), the biochemical-progression-free survival (bPFS), 
and the disease-progression-free survival (dPFS) rates. 
The results of the Kaplan–Meier univariate survival 
analysis as well as the 5-year survival are presented in 
Table 2. For 210 patients in the study, the mean OS 
was 92%, bPFS 42%, and dPFS 82%. Age was not a 
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significant factor influencing survival in this study. A 
lower T stage was associated with a better OS (96% vs. 
88%, p = 0.01) and bPFS (48% vs. 36%, p = 0.02), but 
not dPFS. Similarly, a lower Gleason score was related 
to a better OS (p = 0.02) and dPFS (p = 0.003) and not 
significantly with a better bPFS (p = 0.07). The PSA 
level was important for both bPFS (p = 0.02) and dPFS 
(p = 0.02) but not for OS (p = 0.34). Treatment outco-
mes were better in the RT as compared to the RP group: 
OS – 97% vs. 91%, bPFS – 48% vs. 41%, dPFS – 92% 
vs. 80%. However, the Kaplan–Meier survival analysis 
showed no statistically significant difference between pa-
tients treated with surgery or radiotherapy. Statistically 
significant results are presented in Figures 1–3.
The Cox multivariate survival analysis was conducted 
to determine the prognostic value of the significant cli-
nical and pathological features (Table 3). The variables 
studied included T stage (T2b–T2c vs. T3), the Glea-
son score at biopsy (≤6 vs. 7 vs. ≥8), PSA level (<10 vs. 
10–20 vs. >20 ng/ml), and treatment modality (RP vs. 
RT). The variables had an uneven impact on the three 
outcome measures. A lower T stage was an independent 
predictor of a better OS (p = 0.01) and bPFS (p = 0.03). 
Only the highest Gleason score ≥8 was significantly 
Table 1. Baseline characteristics of the study group
Parameter RP(N = 174) RT (N = 36)
  N % N %
Mean age (yr) (range) 62.7 (44–77) 64.0 (53–75)
< 65 95 54.60 17 47.22
>= 65 79 45.40 19 52.78
T stage
T2b–T2c 100 57.47 5 13.89
T3 74 42.53 31 86.11
Biopsy Gleason
Gleason ≤6 127 72.99 28 77.78
Gleason 7 33 18.97 7 19.44
Gleason ≥8 14 8.05 1 2.78
Mean PSA level (ng/mL) (range) 21.3 (2.01–214.6) 14.1 (3.1–51.0) 
< 10 83 47.70 15 41.67
 10–20 32 18.39 16 44.44
> 20 59 33.91 5 13.89
Treatment centre
NCC 92 52.87 -  
NVI 82 47.13 36 100.00
Adjuvant therapy
No 147 84.48 3 8.33
Yes 27 15.52 33 91.67
Biochemical progression 99 56.90 23 63.89
Disease progression 33 18.97 4 11.11
Deaths 18 10.34 2 5.56
Deaths from cancer 11 6.32 1 2.78
Mean followup (yr) (range) 5.6 (1.1–7.9) 6.6 (4.1–8.8)
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Table 2. 5-year survival and results of univariate analysis in high-risk prostate cancer patients
Parameter 
OS log rank, 
p
bPFR  log rank, 
p
dPFR  log rank, 
pRate 95% CI Rate 95% CI Rate 95% CI
Total 91.9 87 94.9   42 34.5 49.4   81.6 74.5 86.8  
Age                        
< 65 91.4 84.1 95.5 0.92 45.3 34.8 55.1 0.78 85.7 76.4 91.5 0.32
>= 65 92.4 84.8 96.3   38.6 27.8 49.3   77 65.2 85.3  
T stage                        
T2b–T2c 96 89.8 98.5 0.01 48.4 37.5 58.5 0.02 82.3 72 89.1 0.94
T3 87.5 79 92.7   35.7 25.5 46   81.1 70.5 88.2  
Gleason at biopsy                        
Gleason ≤6 93.6 88.1 96.7 0.02 44.4 35.3 53 0.07 82.7 74 88.8 0.003
Gleason 7 92.5 78.5 97.5   40.4 24.6 55.7   88.6 72.3 95.6  
Gleason ≥8 70.5 38.9 87.9   25 6.88 48.8   53.3 26.3 74.4  
PSA level (ng/mL)                        
< 10 92.6 85.1 96.4 0.34 51.5 39.4 62.2 0.02 90.8 82.4 95.3 0.02
10–20 95.6 83.4 98.9   37.3 22.5 52   78.6 61.4 88.8  
> 20 87.8 76 94   32.2 20.5 44.4   69.8 53.8 81.2  
Treatment                        
RP 90.6 84.9 94.3 0.25 40.7 32.4 48.8 0.65 79.8 71.9 85.6 0.15
RT 97.2 81.9 99.6   47.9 29.2 64.3   91.6 69.9 97.9  
Figure 1. The Kaplan–Meier analysis of OS (a), bPFS 
(b), and dPFS (c) stratified for T stage in high-risk 
prostate cancer patients
(a)
(b)
(c)
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Figure 2. The Kaplan–Meier analysis of OS (a), bPFS (b), 
and dPFS (c) stratified for PSA level in high-risk prostate 
cancer patients
Figure 3. The Kaplan–Meier analysis of OS (a), bPFS (b), 
and dPFS (c) stratified for the Gleason score sum in high-
risk prostate cancer patients
(a)
(b)
(c)
(a)
(b)
(c)
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predictive of a worse OS (p = 0.05), bPFS (p = 0.02) 
and dPFS (p = 0.001). The PSA level was not a predictor 
of OS; however, the high PSA level was predictive of a 
worse bPFS (p = 0.007 for PSA ≥20) and a worse dPFS 
(p = 0.01 for the PSA level 10–20, p = 0.008 for ≥20). 
The treatment modality (RP vs. RT) in this study was 
insignificant after the T stage, Gleason score and PSA 
level adjustment for OS, bPFS survival, and dPFS sur-
vival (p = 0.17, p = 0.39, p = 0.20).
Discussion
The comparative effectiveness of local prostate cancer 
treatment is recognized as one of the top 25 research is-
sues by the Institute of Medicine [11]. Despite the need 
to solve this question, to our knowledge, no convincing 
randomized clinical trial has been published yet. There 
are trials comparing outcomes of surgery with watchful 
waiting [12, 13] and surgery with RT in low-risk pro-
state cancer [14], but RP vs. RT in high-risk prostate 
cancer is still a heated debate. Meanwhile, it is possible 
to shed some light on the question with retrospective 
studies. 
Treatment option was not an independent predictor 
of outcome in this study. Although the OS, bPFS and 
dPFS were slightly higher in the RP group, the diffe-
rence was statistically insignificant. A few explanations 
could be given: either the treatment modalities are 
equally effective or there are some drawbacks in our 
study. Our study population was quite small (N = 210), 
especially the RT group (N = 36). Although we consi-
dered many confounding variables (age, T stage, biopsy 
Gleason score, pretreatment PSA level), some were left 
out, e.g., comorbidity. On the other hand, there is some 
evidence that comorbidity (the Charlson comorbidity 
index) is not a better predictor of survival than age [15], 
especially for cancer-specific survival [16]. It would be 
useful to compare cancer-specific survival (CSS) with 
overall survival (OS) in both treatment groups to check 
for significant differences. In this study, CSS was very 
low (results not shown) because of the moderately small 
patient population and follow-up time, therefore, it was 
not analyzed here. 
The study found that the T stage, Gleason score and 
pretreatment PSA level were independent predictors of 
OS or disease progression. These parameters were found 
to predict outcome independently of the treatment in 
other studies as well [16–18]. Particularly predictive of 
a worse outcome in our study was the Gleason score ≥8. 
The PSA level was a significant independent predictor of 
bPFS and dPFS, but not OS. Similarly, Denham et al. 
Table 3. Cox multivariate regression analysis of survival in high-risk prostate cancer patients
Parameter
OS  p 
value
bPFR p 
value
dPFR p 
valueHR 95% CI HR 95% CI HR 95% CI
T stage
T2b–T2c Ref. – – – Ref. – – – Ref. – – –
T3 3.76 1.31 10.78 0.01 1.52 1.04 2.24 0.03 1.14 0.58 2.24 0.71
Gleason at biopsy
Gleason ≤6 Ref. – – – Ref. – – – Ref. – – –
Gleason 7 1.43 0.49 4.20 0.51 1.49 0.94 2.37 0.09 1.59 0.66 3.85 0.30
Gleason ≥8 3.33 1.03 10.79 0.05 2.09 1.13 3.88 0.02 3.84 1.68 8.77 0.001
PSA level (ng/mL)
< 10 Ref. – – – Ref. – – – Ref. – – –
 10–20 0.70 0.19 2.63 0.60 1.50 0.94 2.40 0.09 3.20 1.27 8.07 0.01
> 20 1.38 0.52 3.70 0.52 1.85 1.19 2.90 0.007 3.07 1.34 7.07 0.008
Treatment
RP Ref. – – – Ref. – – – Ref. – – –
RT 0.34 0.07 1.58 0.17 0.80 0.47 1.34 0.39 0.47 0.15 1.49 0.20
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[19] found that the high pretreatment PSA was a strong 
predictor of biochemical recurrence but not of cancer-
specific survival once recurrence had happened. Accor-
ding to the authors, this could be due to the small but 
significant subgroup of patients with aggressive locally 
advanced prostate cancer which exhibits low pretreat-
ment PSA levels. In such patients, the low pretreatment 
PSA could even be a predictor of a worse cancer-specific 
(and thus overall) survival. 
A drawback of our study was rather small and hete-
rogeneous patient population. Patients from two cancer 
centers were pooled to increase the sample size and 
the ability to generalize the results, thus rendering the 
study more valid. It was possible to pool the patients as 
treatment protocols did not differ in the two centers. 
However, it could have been more difcult to control 
for the confounding variables in such a mixed patient 
population. Again, this problem could be solved with a 
larger study population.
The mean follow-up time in this study was 5.6 years 
for RP and 6.6 years for RT groups. It is comparable 
or a little shorter than the follow-up in similar studies 
[17, 20]. However, it could be argued that the follow-
up for prostate cancer patients should be longer to be 
sufcient. With a longer follow-up, additional survival 
benefits could have showed up in one of the treatment 
groups. Prostate cancer usually progresses particularly 
slowly, and even after biochemical recurrence only a 
minority of patients die from cancer-specific causes [21]. 
Therefore, to track the outcomes of the therapy more 
accurately, cancer-specific (or overall) survival with a 
long (e.g., 10 or 15 years) follow-up should be preferred 
over bPFS with a shorter follow-up. 
The quality of life is another issue for high-risk pro-
state cancer patients. Cancer-specific mortality is very 
low even in high-risk prostate cancer patients after any 
radical treatment [22]. As overall survival differs mini-
mally with either treatment (RP or RT), the subsequent 
quality of life becomes crucially important. We did not 
analyze the quality of life after a certain treatment in 
this study; however, there are results from other studies. 
In a study with patients comparable at baseline [23], 
RT was found to be at least as good as RP, with even 
better results in sexual and urinary domains. Nicolaisen 
et al. [24] found no apparent long-term quality of life 
difference with respect to treatment modality (RP, RT or 
RP + RT). The exact outcomes for treatments compared 
were slightly different (e.g., RT was associated with a 
better urinary function). Interestingly, pretreatment 
information and patient education had a more signi-
ficant improvement on patient quality of life than the 
treatment option itself. A useful way to quantify the 
quality of life after treatment is calculating the quali-
ty-adjusted life years. Using the constructed model and 
literature facts, Parikh and Sher [25] found that RT with 
hormone therapy was superior to RP with RT, resulting 
in a higher quality-adjusted life expectancy, especially in 
patients who tolerated hormone therapy well. 
Another approach to compare two treatment moda-
lities which yield very similar results is their cost. In a 
hypothetical model, Cooperberg et al. [26] found that 
differences in outcomes, expressed in quality-adjusted 
life years, were small. However, the difference in costs 
of RT and RP was substantial – the cost for RT was 
essentially higher. This fact could also be considered, 
especially if RP and RT prove to have the same efcacy 
in larger randomized trials as well.
New treatment options have become commonplace 
since most of the retrospective studies (including ours) 
had been conducted: primary androgen deprivation, 
cryotherapy, brachytherapy. Original treatment 
modalities have been improved too with intensity-
modulated or proton beam radiation therapy and 
laparoscopic or robotic-assisted radical prostatectomy. 
Therefore, it might be useful to supplement the future 
comparative effectiveness studies with these new tre-
atment options.
Conclusion
The T stage, Gleason score and pretreatment PSA level 
are significant factors for OS, bPF survival and dPF sur-
vival of prostate cancer patients. Treatment option was 
not an independent predictor of survival in this study.
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